Key points from article :
A new report argues that the next generation of PROTACs – a promising class of drugs that remove harmful proteins rather than simply blocking them – will require a fundamentally different approach to development. Researchers say lessons learned from conventional medicines are not enough because PROTACs work by harnessing the cell's own protein disposal system to destroy disease-causing proteins, opening up possibilities for treating conditions that have long been considered "undruggable".
Unlike traditional drugs, PROTACs rely on a complex interplay between the target protein, the drug molecule and the cell's protein degradation machinery. This means scientists must carefully optimise factors such as molecular structure, stability, distribution within the body and the efficiency of protein degradation, rather than focusing solely on how tightly a drug binds to its target. Experts argue that these unique challenges call for a new "playbook" for drug discovery and development.
Several PROTAC-based therapies are already advancing through clinical trials, particularly for cancer, and researchers believe the technology could eventually be applied to neurological disorders, autoimmune diseases and other conditions driven by harmful proteins. However, the report emphasises that developing successful PROTAC medicines will depend on integrating advances in chemistry, biology and pharmacology from the earliest stages of research.
Although the field is still evolving, PROTACs are widely regarded as one of the most exciting new approaches in drug discovery. By eliminating disease-causing proteins instead of merely inhibiting them, they have the potential to expand the range of treatable diseases and transform the future of precision medicine.
